This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	<b>EMLc submitted</b>	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2025)	Global Fund ERP recommended	GDF Catalog
Amoxicillin/clavulanate 500mg/125mg tablet											
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension											
Bedaquiline 20mg tablet											
Bedaquiline 100mg tablet											
Clofazimine 50mg tablet/capsule											
Cycloserine 125mg capsule											
Delamanid 25mg dispersible tablet											

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: July 2025







**Status** Yes No

N/A

Ineligible for inclusion



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2025)	Global Fund ERP recommended	GDF Catalog	
Delamanid 50mg tablet												
Ethambutol 50mg dispersible tablet												
Ethambutol 100mg dispersible tablet												
Ethambutol 100mg tablet												
Ethionamide 125mg dispersible tablet												
Isoniazid 50mg dispersible tablet												
Isoniazid 100mg dispersible tablet												

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: July 2025







**Status** Yes No

N/A

Ineligible for inclusion



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ E01 (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2025)	Global Fund ERP recommended	GDF Catalog
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Levofloxacin 100mg dispersible tablet											
Linezolid 150mg dispersible tablet											
Linezolid 600mg tablet											
Meropenem 1000mg vial											
Moxifloxacin 100mg dispersible tablet											

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: July 2025







**Status** Yes No

N/A

Ineligible for inclusion



This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (Children & Adolescent '22)	WHO Rapid Communication (DR-TB '24)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2024)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2025)	Global Fund ERP recommended	GDF Catalog	Status  Yes  No Ineligible for inclusion  N/A
Moxifloxacin 400mg tablet/capsule												
PAS Sodium 4gm/5.52gm powder												
Pyrazinamide 150mg dispersible tablet												

DR-TB: Drug-Resistant TB EML: Essential Medicines List EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: July 2025







